Cancer Treatment Reviews
Volume 30, Issue 6 , Pages 589-593, October 2004

Autologous tumour cell vaccine may reduce risk of tumour progression in people with primary renal cell carcinoma:☆☆☆☆☆

Abstracted from: Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363:594–599.

BC Cancer Agency, Vancouver, Canada

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Sources of funding: LipoNova (Hannover, Germany).

☆ For Correspondence Prof. Dieter Jocham, Department of Urology, University of Lubeck Medical School, Ratzeburger Allee 160, 23538 Lubeck, Germany. E-mail: prof.jocham.mul@t-online.de.

☆☆☆ Abstract provided by Bazian Ltd., London.

PII: S0305-7372(04)00122-7

doi:10.1016/j.ctrv.2004.06.006

Cancer Treatment Reviews
Volume 30, Issue 6 , Pages 589-593, October 2004

Article Tools